Meeting Overview - The shareholder meeting was held on November 14, 2025, at the company's headquarters in Beijing [1] - The meeting was convened by the board of directors and was conducted both in-person and via online voting, presided over by Chairman Li Hongming [1] Attendance - All 9 current directors attended the meeting, along with the board secretary and senior management [2] - A witnessing lawyer from a reputable law firm was also present [2] Agenda and Resolutions - A key agenda item was the proposal for the provision of bad debt reserves for receivables, which was approved [3] - The voting process was non-cumulative, and the proposal required separate voting for minority investors [3] Legal Verification - The meeting was witnessed by lawyers from a well-known law firm, confirming that the procedures followed were in compliance with relevant laws and regulations [4][5] - The lawyers concluded that the meeting's convening, attendance, and voting processes were all legally valid [5]
陕西康惠制药股份有限公司 2025年第三次临时股东会决议公告